Growth Plus Reports Logo.jpg
Eosinophilic Esophagitis Market Size to Surpass US$ 941.8 million by 2031 - Growth Plus Reports
February 09, 2024 05:30 ET | Growth Plus Reports
Pune, Feb. 09, 2024 (GLOBE NEWSWIRE) -- According to the latest report published by Growth Plus Reports, the global Eosinophilic Esophagitis Market is expected to clock US$ 941.8 million by 2031 and...
Regeneron Logo.jpg
Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)
January 25, 2024 14:29 ET | Regeneron Pharmaceuticals, Inc.
Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared to placebo Expanded indication marks second disease for...
Logo on white.png
EsoCap reports positive topline results from ACESO Phase II trial investigating ESO-101 in eosinophilic esophagitis
December 05, 2023 03:00 ET | EsoCap AG
ESO-101, EsoCap's lead product candidate, consists of a capsule with a rolled-up, thin mucoadhesive film with the anti-inflammatory corticosteroid, mometasone furoateEsoCap's novel targeted delivery...
Logo.png
Eosinophilic Esophagitis Market to Show Positive Growth by 2032, Examines DelveInsight | Key Companies - Bristol Myers Squibb, Ellodi, AstraZeneca, Kyowa Kirin, Allakos, Pfizer, Revolo, EsoCap AG, NexEos Diagnostics, Celgene
September 28, 2023 13:00 ET | DelveInsight Business Research LLP
New York, USA, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Eosinophilic Esophagitis Market to Show Positive Growth by 2032, Examines DelveInsight | Key Companies - Bristol Myers Squibb, Ellodi, AstraZeneca,...
Logo on white.png
EsoCap completes patient recruitment in ACESO Phase II trial in eosinophilic esophagitis
September 05, 2023 03:30 ET | EsoCap AG
EsoCap's novel targeted delivery platform is designed to increase mucosal contact time and drug deposition in the esophagus ESO-101, EsoCap's lead product candidate, consists of a capsule with a...
An Old Dog with a Ne
An Old Dog with a New Trick… Ellodi’s APT-1011 Promises EoE Patients a Convenient and Potent Treatment Alternative
August 15, 2023 15:40 ET | Spherix Global Insights
Exton, Pennsylvania, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Since launching in May 2022, Sanofi/Regeneron’s Dupixent has been well received by gastroenterologists and allergists as an advancement for...
New Report: Life with EoE
New Study on the Current State of Health Care for Eosinophilic Esophagitis
May 18, 2023 15:03 ET | Asthma and Allergy Foundation of America
Washington, D.C., May 18, 2023 (GLOBE NEWSWIRE) -- A groundbreaking report reveals challenges and barriers to timely diagnosis and effective treatment and management of a rare, but increasing...
sphericalinsightsoptionblue.png
Global Eosinophilic Esophagitis Market Size to grow USD 1927 Million by 2030 | CAGR of 34%; Spherical Insights & Consulting
October 31, 2022 07:00 ET | SPHERICAL INSIGHTS LLP
New York, United States , Oct. 31, 2022 (GLOBE NEWSWIRE) -- According to a research report published by Spherical Insights & Consulting, the Global Eosinophilic Esophagitis Market Size to grow...
Featured Image for EnteroTrack LLC
Esophageal String Test®, a Less Invasive Way to Monitor Adults and Children With Eosinophilic Esophagitis (EoE), Launches in the US
October 24, 2022 09:00 ET | EnteroTrack LLC
AURORA, Colo., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Clinicians with the Gastrointestinal Eosinophilic Disease Program at the Digestive Health Institute, Children's Hospital of Colorado, performed the...
Logo on white.png
EsoCap supports first European EoE Day of the European Society of Eosinophilic Oesophagitis on May 22, 2022
May 20, 2022 05:00 ET | EsoCap AG
Patients with eosinophilic esophagitis (EoE) suffer from severe symptoms including swallowing disorders, food impaction, vomiting, and heartburnEsoCap is currently conducting a randomized,...